Project Grant R01DK141535
Award Date
1/1/25
Completion Date
11/30/29
Dollars Obligated
$465K
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $120,375 to Childrens Hospital Medical Center in Cincinnati, Ohio to develop advanced mouse models for studying the pathogenesis of myelodysplastic syndromes (MDS) caused by DDX41 gene mutations. The project aims to create genetic mouse models that accurately reflect the natural progression of DDX41-mutated MDS,...
This federal Project Grant award, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports the development of selective degradation strategies to target mutant transcription factors. The $253,500.00 award will fund experiments to design and test approaches to selectively degrade the mutant variant of the KLF1 transcription factor, which is implicated in...
The Project Grant award R35CA293978, provided by the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research), supports research to identify the mechanisms driving rapid evolution of cancer genomes. The $942,442 award to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, MA will fund investigations into two catastrophic mutational processes in cancer, chromothripsis and chromoplexy. The research aims to better understand the mechanisms of chromosome fragmentation, DNA...
This federal Project Grant award in the amount of $719,873 was provided by the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) to The Trustees of Columbia University in the City of New York, doing business as the Health Sciences Division. The funding supports research to investigate how epigenetic deregulation of osteoblasts in the bone marrow stroma promotes age-related clonality and transformation of hematopoietic cells harboring IDH1/2 mutations, which can...
This federal Project Grant award, valued at $949,056.00 and awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research program, supports research to investigate the functional roles of the DDX41 gene in the homeostasis of G-quadruplexes during erythropoiesis (red blood cell production). The research aims to elucidate how loss of DDX41 function leads to aberrant G-quadruplex accumulation,...
The federal Project Grant award R01HG013083, funded by the National Human Genome Research Institute (NHGRI) under the Human Genome Research Program (CFDA 93.172), provides $1,038,898.88 to the Dana-Farber Cancer Institute, Inc. (DFCI) to develop novel approaches for integrating single-cell data with genome-wide association studies (GWAS) to elucidate the genetic architecture of complex diseases. The key objectives are to: 1) leverage single-cell epigenetic data to identify heritable components...
This Project Grant award of $1,560,024 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research on the intracellular trafficking of the essential signaling metabolite heme in myeloid cells and its impact on physiology and disease. The primary awardee, the Scripps Research Institute, will leverage mouse models, chemical tools, and genetic mutants to investigate...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Vanderbilt University Medical Center (VUMC) a $150,000 Project Grant under CFDA 93.847, the Diabetes, Digestive, and Kidney Diseases Extramural Research program. The grant, which runs from Sep 1, 2023 to Aug 31, 2024, will fund a study to identify factors that contribute to clonal expansion and disease progression in clonal hematopoiesis of indeterminate potential (CHIP). The research aims to dissect the...
This federal Project Grant award, totaling $101,491.00, was made by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program. The grant supports research conducted by Cold Spring Harbor Laboratory (CSHL) to identify inflammatory mediators of clonal hematopoiesis (CH) and evaluate their potential as therapeutic targets. The research project aims to use high-throughput CRISPR/Cas9 screening to find both general and genotype-specific inflammatory dependencies...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will provide $161,922 to investigate the interplay between mutations in the DDX41 and CUX1 genes and their impact on hematopoiesis (blood cell formation) in zebrafish models and human induced pluripotent stem cells (iPSCs). The research aims to elucidate how the co-occurrence of these mutations drives hematopoietic dysfunction and contributes to...